x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

Mendelspod Podcast

Offering a front row seat to the Century of Biology, veteran podcast host Theral Timpson interviews the who"s who in genomics and genomic medicine. www.mendelspod.com

science & medicine natural sciences

All Episodes

45:00

Grail and Verily Alum on Billion Dollar Startup...

Mendelspod Podcast ·

2024/10/17

Vik Bajaj is bullish on genomics in the age of artificial intelligence. A pioneering figure in biotech—co-founder of Verily and Grail—Bajaj now leads Xaira Therapeutics, where he's exploring how AI can revolutionize drug development. In today’s episode, he joins Theral to break down how the intersection of AI and genomics is unlocking new possibilities in drug development, with the potential to accelerate every stage of drug discovery.Bajaj explains that at Xaira, machine learning and advanced

en

24:19

Singular Genomics Introduces a Dual-Purpose Platform...

Mendelspod Podcast ·

2024/10/15

Singular Genomics launched its fast and flexible mid-throughput sequencing platform, the G4, in the heady days of the pandemic when we saw a renaissance in new technologies and companies.At AGBT earlier this year, the company unveiled its latest offering in development, the G4X Spatial Sequencer, an upgrade to the G4 that unlocks the system to perform high-throughput in situ multiomics. The platform will be capable of simultaneous direct RNA sequencing, targeted transcriptomics, proteomics, and

en

35:44

The Evolving Future of Genetic Counseling with Ellen...

Mendelspod Podcast ·

2024/09/30

Ellen Matloff is back on the show today to discuss the changing landscape of genetic testing and counseling in 2024. She is the founder and CEO of MyGeneCounsil and a strong advocate for the critical role of genetic counselors in healthcare. She also writes a regular column for Forbes magazine.In 2024, we’ve seen a dramatic transformation of the genetic testing landscape, with big labs buying the small ones. Ellen says this is “forcing genetic testing to go mainstream.”Surely that’s a good thing

en

26:47

As Sequencing Continues to Scale, Volta Labs Improves...

Mendelspod Podcast ·

2024/09/26

Depending on your age, DNA sequencing is experiencing a second or third renaissance. New sequencing tools continue to make genomics one of the fastest-growing industries of all time. All this scaling can create a bottleneck in sample prep. Volta Labs, a company founded out of the MIT Media Lab by Udayan Umapathi, has just commercialized a new instrument for sample prep called Callisto. The instrument manipulates samples with electric, magnetic, and acoustic fields. Udayan joins us today to

en

22:33

What’s Next for Large-Scale Proteomics? With Chris...

Mendelspod Podcast ·

2024/09/19

Genetic studies of human populations have become a major tool for drug development. In the last few years, these studies have moved toward comprehensive proteomics profiling as well. In late 2023, a paper was published in Nature by the Pharma Proteomics Project, which characterized the plasma proteomic profiles of 54,219 UK Biobank participants. This was a precompetitive biopharmaceutical consortium that sought to provide a mapping of 2,923 proteins that identified 14,287 primary genetic

en

5:17

Will this At-Home Blood Collection Device Transform...

Mendelspod Podcast ·

2024/09/17

This is a free preview of a paid episode. To hear more, visit www.mendelspod.comA new blood collection device offered by startup company Tasso is a blood lancet that collects whole liquid blood samples. Its ease of use for at-home collection could dramatically improve patient testing compliance and impact the scale of clinical trials.Ben Casavant is the co-founder and CEO of Tasso. He joins us to discuss the possibilities for at-home testing. Ben and the company have raised over $100 million

en

70:39

Geneticist Kevin Mitchell Attempts to Naturalize Free...

Mendelspod Podcast ·

2024/09/12

Today, we continue “The New Biology” series with a non-reductive geneticist from Trinity College in Dublin. Kevin Mitchell is the author of Free Agents: How Evolution Gave Us Free Will.The problem of free will has dogged philosophers and scientists as much as any question going back to the Greeks. Determinism, typically argued by physicists, usually goes something like: the laws of physics predict the future, and therefore, there is no free will. In our lives, however, the experience of making

en

25:29

ctDNA Testing Could Lead to New Ways of Staging...

Mendelspod Podcast ·

2024/08/27

Today, we go to the frontlines of cancer treatment for a case study on the use of ctDNA testing in the clinic. ctDNA, or circulating tumor DNA, is now used as a biomarker in new testing to detect cancer in a patient’s blood. Oncologists, such as today’s guest, Dr. Ben Weinberg, are increasingly using this testing. Dr. Weinberg is an associate professor of medicine and an attending physician specializing in colorectal cancer at MedStar Georgetown University Hospital.“Even though I give chemotherapy

en

52:14

14th Season Opener: Michael Levin on ‘The New Biology’

Mendelspod Podcast ·

2024/08/22

For over a hundred years, biologists have been working to fully understand biology at the level of chemistry, in other words unite biology with chemistry. This is considered the reductive approach inspired by the unification of chemistry with physics in the early 20th century with the Periodic Table and the Bohr model of the atom. In the attempt to reduce biology to chemistry, the gene has been the star player. The gene linked phenotype to the molecules of chemistry and to the more abstract and

en

31:14

The Success of ctDNA Testing in Colorectal Cancer:...

Mendelspod Podcast ·

2024/08/20

Adham Jurdi was an oncologist at the Austin Cancer Center when the pandemic hit. His cancer patients were a doubly vulnerable population. Office visits, follow-up care — every interaction between the patient and the healthcare system put them at risk for COVID-19 infection, which would hit extra hard because of their compromised immunity. It was then that he discovered a blood test that could monitor the patient’s cancer using ctDNA and keep the patient more at home.Jurdi is now the medical director

en

40:27

Henrik Zetterberg on the Current Excitement Around...

Mendelspod Podcast ·

2024/08/14

Alzheimer’s disease is now one of the hottest areas of research despite little progress in the decades up to about five years ago. The disease was proving especially difficult to diagnose early and to treat.Today researchers are largely on board with the amyloid cascade hypothesis. There are several FDA-approved drugs for treating the disease, with another just around the corner. New biomarkers for Alzheimer’s enabled by a new generation of proteomics tools promise to change care by giving patients

en

44:03

The Reboot of Consumer Genomics? with Kian Sadeghi,...

Mendelspod Podcast ·

2024/08/06

There’s a new company in the consumer genomics space that last month released results for the first adopters of its new consumer-facing whole genome product. Nucleus Genomics, founded by Kian Sadeghi, aims to reinvent direct-to-consumer genomic testing with "the consumer reach of 23andMe and the clinical consequence of Myriad Genetics.”Kian joins us today to talk about his vision for the company and why consumer genomics is still a great idea.“To know that we can potentially give someone an insight

en

5:09

From Geospatial to Biospatial: Avi Veidman of Nucleai

Mendelspod Podcast ·

2024/07/25

This is a free preview of a paid episode. To hear more, visit www.mendelspod.comAvi Veidman spent over 20 years in the IDF (Israel Defense Forces), leading multi-disciplinary teams in the use of AI, machine learning, and data science. One of his key projects involved developing systems that mapped the world with satellite images to spot adversaries from space. Upon retirement, he co-founded Nucleai with a couple of his former defense colleagues, believing that the AI technology they had seen and

en

26:19

New Proteomics Technology Brings Unprecedented...

Mendelspod Podcast ·

2024/07/18

Yuling Luo is a serial entrepreneur who has founded three significant companies in life science tools. Most recently, he is the founder and CEO of Alamar Biosciences which this year commercially launched its ARGO HT instrument as well as a powerful new panel to detect inflammatory proteins called NULISA.Before founding Alamar, Luo was the founder and CEO of Advanced Cell Diagnostics, which was acquired by BioTechne in 2016. He was also a co-founder of Panomics, which was scooped up by

en

7:30

Diagnostic Trends in 2024 with Mara Aspinall,...

Mendelspod Podcast ·

2024/06/27

This is a free preview of a paid episode. To hear more, visit www.mendelspod.comOne might think the pandemic would have been good for diagnostic companies. So why the financial hangover?Mara Aspinall has 30 years of leadership in genomics and the diagnostics industry. This has led her to her current role as a new partner at Illumina Ventures, a venture fund independent from Illumina that is focused on funding diagnostics and tools companies.Mara publishes the fantastic newsletter Sensitive and

en

26:38

The Actionable Epigenome with Bret Barnes, Illumina

Mendelspod Podcast ·

2024/06/18

The genome has been the core focus of biomedical research for twenty years. Although the genome is prewritten and predetermined, much biology happens after it appears. One area is epigenomics, which is the modification of genomic outcomes.Bret Barnes has spent his career at Illumina developing the DNA methylation Infinium arrays that have become the workhorse of epigenomic studies around the world. Barnes says he was torn as a young person between biochemistry and computer science. He fortuitously

en

6:04

Not All Prenatal Screens Are the Same: Jennifer...

Mendelspod Podcast ·

2024/06/13

This is a free preview of a paid episode. To hear more, visit www.mendelspod.comNot content to offer “me too” products, a new company in the prenatal arena, Billion to One (BTO), is reimagining prenatal testing. Last year, their new Unity Fetal Risk Screen was featured in the American Journal of Human Genomics as a top advancement in applying genomics to clinical care. Joining us today is Jennifer Hoskovec, Senior Director of Medical Affairs at BTO. She says the new Unity Screen offers two steps in

en

30:20

Harvard's Marc Lipsitch on the New White House Policy...

Mendelspod Podcast ·

2024/06/04

This week, we saw Dr. Anthony Fauci being grilled by an angry congress over, among other things, the origin of COVID-19, which is estimated killed at least 25 million people. He was asked about how the National Institute of Allergy and Infectious Diseases, which he directed until 2022, funded risky virus research at the Wuhan lab in China.Ever since the pandemic broke out, scientists, as well as policymakers, have been debating new restrictions on pathogen research, and last month, the White House

en

24:12

Liquid Biopsy Goes Beyond Cancer: Diana Abdueva and...

Mendelspod Podcast ·

2024/05/23

A new precision medicine startup has launched that uses transcriptomic and epigenetic information to help with therapy for a wide range of chronic disorders. Hayward, California-based Aqtual emerged from stealth at the end of last year with data on its first assay, a blood-based test for rheumatoid arthritis.Today, we’re joined by Diana Abdueva, Aqtual’s Founder and CEO, and Maggie Louie, VP of Translational Research and Strategic Partnerships."We are complex organisms that work beautifully for many

en

6:17

Cell Therapy Will Transform Medicine as We Know It,...

Mendelspod Podcast ·

2024/05/16

This is a free preview of a paid episode. To hear more, visit www.mendelspod.comToday, we pursue an exciting area of medicine for the first time: cell therapy for solid tumors.Most, if not all, of our audience will be familiar with the success of CAR-T therapies for blood cancers. But only 10% of cancer is in the blood. The other 90% develop solid tumors. Jason Bock is the CEO and founder of CTMC, a new company aiming to speed the advancement of the entire field of cell therapies. First, we cover

en

516 results

Similar Podcasts

科学史评话最新专辑

科学史评话

Hablando con Científicos - Cienciaes.com

cienciaes.com

天方烨谈

基因频道

The Permaculture Podcast

Scott Mann

汪诘：科学有故事（主打）

科学有故事